Orforglipron (Foundayo): The First Non-Peptide GLP-1 Pill

Orforglipron is a once-daily, oral, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly. It was discovered by Chugai Pharmaceutical Co. and licensed by Lilly in 2018, and the two companies published its preclinical pharmacology together. On 1 April 2026 the FDA approved it under the brand name Foundayo for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, used alongside a reduced-calorie diet and increased physical activity.

The approval was unusually fast. Foundayo was the first new molecular entity cleared under the FDA Commissioner’s National Priority Voucher pilot, a programme designed to compress review timelines for medicines judged to be national health priorities. The clearance came roughly 50 days after Lilly filed, and 294 days before the application’s scheduled review date of 20 January 2027. The FDA described it as the fastest approval of a new molecular entity since 2002.

Its defining feature is convenience. Unlike injectable GLP-1s such as semaglutide and tirzepatide, and unlike the oral semaglutide formulation (Rybelsus, and the oral Wegovy weight-loss version approved in December 2025), which must be taken fasting with a small sip of water and a 30-minute wait before eating, Foundayo can be taken at any time of day with no food or water restrictions and needs no refrigeration. Lilly’s chief executive has positioned it not as the most potent GLP-1 but as the most accessible one, a needle-free entry point for people who have avoided the class.

Lilly has submitted orforglipron to regulators in more than 40 countries and is studying it well beyond obesity, with active programmes in type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis, hypertension, peripheral artery disease and stress urinary incontinence. A US filing for type 2 diabetes was planned for the middle of 2026.

Orforglipron activates the GLP-1 receptor, the same target as injectable GLP-1 drugs, but it is not a peptide. It is a small molecule, which is why it survives digestion and is absorbed orally without the protective formulation that peptide drugs require. Activating the receptor increases feelings of fullness, slows gastric emptying, and stimulates glucose-dependent insulin secretion, which together reduce calorie intake and lower blood sugar.

Because it is a conventional small molecule, orforglipron is processed by the liver’s CYP3A4 enzyme system. That has a practical consequence: strong CYP3A4 inducers can lower its blood levels and blunt its effect, so its activity may need monitoring when combined with such medicines. This is ordinary small-molecule pharmacology, and it is part of what separates orforglipron from the peptide GLP-1s.

This distinction matters for anyone researching “peptides”. Despite being grouped with peptide therapeutics in popular coverage, orforglipron is a synthetic small molecule, in the same not-a-peptide category as MK-677 and 5-Amino-1MQ.

The bottom line: orforglipron reaches the GLP-1 receptor as an orally absorbed small molecule rather than an injected peptide, which is what makes a daily pill possible.

The FDA-approved Foundayo label describes six tablet strengths (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg) and a gradual upward titration, so the body can adjust and gastrointestinal effects stay manageable. Under the label the regimen begins at the lowest starter strength, steps up at 30-day intervals through the intermediate strengths, and is capped at a once-daily maximum strength, with most people settling on a maintenance strength reached over roughly three to four months. This is the prescribing schedule a clinician follows, not a self-administration protocol; Foundayo is a prescription medicine titrated under medical supervision.

The label also notes that the tablet is taken once daily, swallowed whole, and may be taken at any time of day with or without food, which is part of what distinguishes it from oral semaglutide. The slow escalation is what keeps nausea and vomiting in check, which is why the published trials and the label both build in the 30-day steps rather than starting at a high strength.

One point causes confusion when comparing the label to the trial papers. The pivotal studies used an earlier investigational formulation dosed up to 36 mg, and the published results report those figures, whereas the commercial tablet was reformulated and its label re-expresses the same drug exposure as equivalent commercial strengths. In short, the 36 mg of the research papers and the top commercial strength describe the same exposure, not two different doses.

The bottom line: the approved label describes a once-daily tablet taken at any time with or without food, titrated gradually under a prescriber from the starter strength to its maximum strength over about three to four months.

Foundayo’s approval rests on the Phase 3 ATTAIN obesity programme, while a parallel ACHIEVE programme tested it in type 2 diabetes. Together these are high-tier human evidence, peer-reviewed and large in scale, not preclinical or observational data.

ATTAIN-1 (obesity, no diabetes)

Published in The New England Journal of Medicine, ATTAIN-1 enrolled 3,127 adults with obesity or overweight. At the highest dose, participants lost an average of 27.3 lb (12.4%) of body weight at 72 weeks on the efficacy estimand, against 0.9% on placebo. Among them, 59.6% lost at least 10% of their body weight and 39.6% lost at least 15%. Of the participants who had prediabetes at baseline, up to 91% reached near-normal blood sugar versus 42% on placebo.

ATTAIN-2 (obesity plus type 2 diabetes)

Published in The Lancet, ATTAIN-2 enrolled adults with obesity and type 2 diabetes. The highest dose produced 22.9 lb (10.5%) mean weight loss at 72 weeks versus 2.2% on placebo, with HbA1c reductions of 1.3% to 1.8% from a baseline of 8.1%, and an exploratory 50.6% drop in high-sensitivity C-reactive protein, an inflammation marker. Treatment discontinuation for adverse events ran 6.1% to 9.9% versus 4.1% on placebo, and of ten deaths recorded across the trial, investigators judged none related to orforglipron.

ACHIEVE-3 (head-to-head against oral semaglutide)

ACHIEVE-3, published in The Lancet in February 2026, was the first head-to-head Phase 3 trial of two oral GLP-1 receptor agonists. It randomised 1,698 adults with type 2 diabetes inadequately controlled on metformin to orforglipron or oral semaglutide over 52 weeks. Orforglipron beat oral semaglutide on every primary and key secondary endpoint: at the top doses it lowered HbA1c by 2.2% versus 1.4% for oral semaglutide, and produced 19.7 lb (9.2%) weight loss versus 11.0 lb (5.3%), a 73.6% greater relative weight loss, with separation appearing within four weeks. It is the clearest signal yet that an oral small molecule can outperform the leading oral peptide.

ACHIEVE-4 (longest study, cardiovascular safety)

ACHIEVE-4 is the longest and largest orforglipron study to date, enrolling more than 2,700 adults with type 2 diabetes across 15 countries and running out to 104 weeks against insulin glargine. It met its primary cardiovascular safety endpoint, showing non-inferiority with a 16% lower observed rate of major adverse cardiovascular events, alongside greater HbA1c and weight reductions and a striking exploratory finding of 57% lower all-cause mortality. A thorough analysis of potential drug-induced liver injury found no hepatic safety signal, consistent with every prior study in the ATTAIN and ACHIEVE programmes. Discontinuation for adverse events over the minimum 52-week period was 10.6%.

Trial (highest dose)	Population	Headline result	Journal / status
ATTAIN-1	Obesity, no diabetes	12.4% (27.3 lb) at 72 wk	NEJM
ATTAIN-2	Obesity + type 2 diabetes	10.5% (22.9 lb), A1c down 1.3 to 1.8%	The Lancet
ACHIEVE-3	Type 2 diabetes (vs oral semaglutide)	A1c 2.2% vs 1.4%, weight 9.2% vs 5.3%	The Lancet
ACHIEVE-4	Type 2 diabetes (vs insulin glargine, 104 wk)	CV safety met, 16% lower MACE, no liver signal	Reported topline

For context, orforglipron’s obesity numbers sit in the range of second-generation GLP-1s on weight and glycaemic benchmarks. It does not match the larger losses seen with the dual agonist tirzepatide or the investigational triple agonist retatrutide, and Lilly has been open that its advantage is the oral route rather than peak potency.

The bottom line: in ATTAIN-1 the highest orforglipron dose produced its peak average weight loss at 72 weeks, and in ACHIEVE-3 it outperformed oral semaglutide on both blood sugar and weight.

Foundayo launched at a price well below the injectable GLP-1s. Through Lilly’s direct-to-patient channel, LillyDirect, self-pay costs run from $149 a month at the 0.8 mg starter dose to $349 a month at the highest strengths, with maintenance doses around $299. Eligible patients with commercial insurance that covers the drug can pay as little as $25 a month with a savings card, and from 1 July 2026 eligible Medicare Part D beneficiaries may pay roughly $50 a month. For comparison, the injectable weight-loss products carry list prices above $1,000 a month, and oral semaglutide is priced close to its injectable form.

Part of the reason a pill can be cheaper is manufacturing. A small molecule is far simpler and more scalable to produce than an injectable peptide, which needs sterile fill-finish and cold-chain handling. Lilly’s leadership has been careful to say that simpler production “may” support affordability rather than promising it, but the launch pricing landed below several pre-approval analyst forecasts. Foundayo is dispensed through LillyDirect, licensed retail pharmacies and legitimate telehealth services, and always requires a prescription from a clinician.

The bottom line: Foundayo self-pay runs a few hundred dollars a month, far below the $1,000-plus injectables, helped by the lower cost of making a small-molecule pill.

Orforglipron is approved in the United States and under review elsewhere. Lilly has filed in more than 40 countries, so European, UK and Australian decisions are pending rather than complete, and the US diabetes indication was filed separately during 2026.

Region	Status	Notes
United States	Approved	Foundayo, weight management; diabetes filing submitted
United Kingdom	Under review	MHRA decision pending
European Union	Under review	EMA evaluation ongoing
Australia	Under review	TGA decision pending

The bottom line: orforglipron is FDA-approved as Foundayo in the United States and remains under regulatory review in the UK, EU and Australia.

Orforglipron’s safety profile is consistent with the GLP-1 class, and the most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, decreased appetite and constipation, mostly mild to moderate and concentrated during dose escalation. In the obesity trials, severe gastrointestinal reactions occurred in roughly 3% of treated participants versus 1% on placebo, and discontinuation for adverse events rose with dose. The drug is not recommended in people with severe gastroparesis, and it is not intended for use alongside other GLP-1 receptor agonists.

The liver question

Liver safety is worth understanding precisely, because earlier oral GLP-1 candidates were abandoned over hepatic toxicity. Across the entire ATTAIN and ACHIEVE programme, including the 104-week ACHIEVE-4 analysis, orforglipron showed no drug-induced liver injury signal. However, because the fast approval pathway meant less long-term exposure data than usual, the FDA made monitoring a condition of clearance: as part of its post-marketing requirements, Lilly must continue assessing drug-induced liver injury and major adverse cardiovascular events in ongoing trials, conduct at least 15 years of thyroid cancer follow-up, and maintain pregnancy and paediatric registries. Separately, after launch the FDA received a small number of spontaneous reports of serious liver events, including one case of liver failure, which are under routine post-marketing surveillance. Such reports do not establish that the drug caused the events, and Lilly has reiterated that no hepatic safety signal has been seen across the Phase 3 programme. The label advises against use in severe hepatic impairment, while no dose change is needed in mild or moderate impairment or in renal impairment.

Oral contraceptives and the boxed warning

The label carries a practical warning that oral contraceptives may be less effective on Foundayo, likely because delayed gastric emptying alters absorption. People using the pill are advised to switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase. Foundayo also carries the GLP-1 class boxed warning for thyroid C-cell tumours and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

The bottom line: side effects are mostly gastrointestinal, no liver signal emerged in trials, but the FDA has mandated long-term liver, heart and thyroid monitoring as a condition of the rapid approval.

Orforglipron sits within the wider GLP-1 and fat-loss landscape. The injectable single-target agonist semaglutide and the dual GIP/GLP-1 agonist tirzepatide are its closest approved comparators, while the investigational triple agonist retatrutide has produced larger weight loss in trials. As a non-peptide small molecule it shares its classification with 5-Amino-1MQ rather than with the peptide GLP-1s. For how unapproved and compounded versions of these drugs are regulated, see our guide to compounded versus branded GLP-1s, and for the wider category see our overview of GLP-1 agonists and fat-loss peptides.

Is orforglipron a peptide?

No. Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor, which is why it can be taken as an oral tablet rather than an injection.

Is orforglipron FDA approved?

Yes. The FDA approved orforglipron as Foundayo in April 2026 for chronic weight management in adults with obesity or overweight plus a weight-related condition.

How much weight do people lose on orforglipron?

In the Phase 3 ATTAIN-1 trial, the highest dose produced an average of about 12% of body weight at 72 weeks, with roughly 60% of participants losing at least a tenth of their starting weight.

How is orforglipron different from oral semaglutide?

Orforglipron is a small molecule taken any time of day with no food or water restrictions, whereas oral semaglutide (Rybelsus and oral Wegovy) must be taken fasting with limited water and a 30-minute wait before eating. In the ACHIEVE-3 trial orforglipron also produced greater blood sugar and weight reductions than oral semaglutide.

How much does Foundayo cost?

Self-pay through LillyDirect runs in the low-to-mid hundreds of dollars a month depending on dose, with eligible commercially insured patients paying as little as $25 and eligible Medicare beneficiaries about $50 from July 2026.

Does Foundayo affect birth control?

Possibly. The label warns that oral contraceptives may work less well on Foundayo, and advises switching to a non-oral method or adding a barrier method for 30 days after starting and after each dose increase.

Is it legal to buy orforglipron as a research compound?

Research-use-only orforglipron is not the approved Foundayo medicine and is not authorised for human use; its identity, purity and dose are unverified, and human use carries legal and safety risk.